could spell avoiding high-risk consequences for companies .
FDA officials have acknowledged that the rapid pace of innovation in the digital health field poses a significant challenge for the agency . They say new regulatory frameworks will be essential to allow the agency to ensure the safety and effectiveness of the devices on the market without unnecessarily slowing progress .
Examples of approaches currently taken by the FDA include routine monitoring of SaMD products by manufacturers to determine when an algorithm change requires FDA review and premarket assessment of SaMD products that require it , among others .
The utilisation of AI in healthcare has the potential to bring about significant changes in patient outcomes , efficiency and cutting times in research and development . As a result , stakeholders – such as healthcare providers , software developers , and researchers – are continually exploring and creating new AI-based products , which push the boundaries of the current regulatory framework . Regulatory bodies , such as the FDA , are working towards addressing these challenges by devising policies that foster innovation while safeguarding public health .
There are , however , many issues that must be addressed to achieve this goal . As these policies are developed , it may also be necessary to consider legislative action to clarify the regulatory ambiguities within the field . mobile-magazine . com 125